Shop til you drop.

At the FedRAMP marketplace.

Y’all. I can’t get off this FedRAMP Marketplace. I had to come with Round 2.

It’s a rabbit hole. Apologies in advance for the length.

Here’s where I started…Data Made Human. Sounds promising. Let’s have a look.

ROSALIND DxM provides real-time SARS-CoV-2 variant surveillance and diagnostic monitoring incorporating international viral sequence data. DxM also includes a comprehensive BioBank of SARS-CoV-2 specimens with sample tracking and workflow management for test panel creation, panel blinding, and results submission across participating labs and organizations. ROSALIND Research provides visual analysis, interpretation, and cloud-based data sharing of genomic datasets produced with Next Generation Sequencing (NGS), NanoString instruments, and other multi-omic methods. ROSALIND Research features analysis pipelines for gene expression and gene regulation studies, including Single-Cell RNA-seq, bulk RNA-seq, miRNA-seq, ATAC-seq, ChIP-seq, and Proteomics. Rosalind uses knowledge graphs to securely store institutional data as searchable libraries while enabling permissions-based data sharing between authorized users and across institutions.

As I read this description, I was surprised by the noticeable absence of usually abundant words like “secure” and “privacy” and “safe”.

Also, there was some familiar verbiage.

Then I realized it’s Throwback Day.

Let’s review a patent.

→ United States Patent 11,107,588: Ehrlich , et al. August 31, 2021

In some embodiments, vaccines are all compounds as disclosed in in the website of the World Health Organization (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines),which are all incorporated herein by reference, and which are optionally provided (e.g., as a kit) with software such as described herein and/or provided with instructions for use targeting potential super spreaders detected, for example, using methods and apparatus as described herein, and include the following:

---

→ Apologies for the following list. It is going to make this post super long…but, like the list of side effects from the Pfizer docs, you kind of need to see it to grasp the magnitude.

---

28 candidate vaccines in clinical evaluation

TABLE-US-00001 COVID-19 Route Vaccine Type of Number Timing of Clinical developer/ Vaccine candidate of of Admin- Stage manufacturer platform vaccine doses doses istration Phase 1 Phase 1/2 Phase 2 Phase 3 University Non- ChAdOx1-S 1 IM PACTR 2020-001228-32 ISR of Oxford/ Replicating 202006922165132 CTN AstraZeneca Viral 2020-001072-15 89951424 Vector Interim Report Sinovac Inactivated Inactivated 2 0, 14 IM NCT04383574 NCT days NCT04352608 04456595 Wuhan Inactivated Inactivated 2 0, 14 or IM Chi Chi Institute of 0, 21 CTR CTR Biological days 2000031809 2000034780 Products/ Sinopharm Beijing Inactivated Inactivated 2 0, 14 or IM Chi Chi Institute of 0, 21 CTR CTR Biological days 2000032459 2000034780 Products/ Sinopharm Moderna/ RNA LNP- 2 0, 28 IM NCT NCT04405076 NCT04470427 NIAID encapsulated days 04283461 mRNA Interim Report BioNTech/ RNA 3 LNP- 2 0, 28 IM 2020-001038-36 NCT FosunPharma/ mRNAs days Chi 04368728 Pfizer CTR 2000034825 CanSino Non- Adenovirus 1 IM Chi Chi Biological Replicating Type 5 CTR CTR Inc./Beijing Viral Vector 2000030906 2000031781 Institute of Vector Study Report Study Report Biotechnology Anhui Protein Adjuvanted 2 or 3 0, 28 IM NCT NCT Zhifei Subunit recombinant or 04445194 04466085 Longcom protein 0, 28, Bio- (RBD- 56 days pharmaceutical/ Dimer) Institute of Microbiology, Chinese Academy of Sciences Institute of Inactivated Inactivated 2 0, 28 IM NCT NCT Medical days 04412538 04470609 Biology, Chinese Academy of Medical Sciences Inovio DNA DNA 2 0, 28 ID NCT Pharma- plasmid days 04447781 ceuticals/ vaccine NCT International with 04336410 Vaccine electro- Institute poration Osaka DNA DNA 2 0, 14 IM NCT University/ plasmid days 04463472 AnGes/ vaccine + Takara Bio Adjuvant Cadila DNA DNA 3 0, 28, lD CTRI/ Healthcare plasmid 56 days 2020/07/026352 Limited vaccine Genexine DNA DNA 2 0, 28 IM NCT Consortium Vaccine days 04445389 (GX-19) Bharat Inactivated Whole- 2 0, 14 IM NCT Biotech Virion days 04471519 Inactivated Janssen Non- Ad26COVS1 2 0, 56 IM NCT Pharma- Replicating days 04436276 ceutical Viral Companies Vector Novavax Protein Full 2 0, 21 IM NCT Subunit length days 04368988 recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M Kentucky Protein RBD- 2 0, 21 IM NCT Bioprocessing, Subunit based days 04473690 Inc Arcturus/ RNA mRNA IM NCT Duke-NUS 04480957 Gamaleya Non- Adeno- 1 IM NCT Research Replicating based 04436471 Institute Viral NCT Vector 04437875 Clover Protein Native 2 0, 21 IM NCT Biopharma- Subunit like days 04405908 ceuticals Inc./ Trimeric GSK/Dynavax subunit Spike Protein vaccine Vaxine Pty Protein Recombinant 1 IM NCT Ltd/Medytox Subunit spike 04453852 protein with Advax .TM. adjuvant University Protein Molecular 2 0, 28 IM ACTRN of Subunit clamp days 12620000674932p Queensland/ stabilized CSL/Seqirus Spike protein with MF59 adjuvant Institute Replicating Measles- 1 or 2 0, 28 IM NCT Pasteur/ Viral vector days 04497298 Themis/ Vector based (not yet Univ. of recruiting) Pittsburg CVR/Merck Sharp & Dohme Imperial RNA LNP- 2 IM ISRCTN College nCoVsaRNA 17072692 London Curevac RNA mRNA 2 0, 28 IM NCT days 04449276 People's RNA mRNA 2 0, 14 IM Chi Liberation or 0, CTR Army 28 days 2000034112 (PLA) Academy of Military Sciences/ Walvax Biotech. Medicago VLP Plant- 2 0, 21 IM NCT Inc. derived days 04450004 VLP adjuvanted with GSK or Dynavax adjs. Medigen Protein S-2P 2 0 28 IM NCT Vaccine Subunit protein + days 04487210 Biologics CpG1018 Corporation/ NIAID/ Dynavax

139 candidate vaccines in preclinical evaluation

TABLE-US-00002 Current stage of Same platform Type of clinical evaluation/ for non- candidate Coronavirus regulatory status- Coronavirus Platform vaccine Developer target Coronavirus candidate candidates DNA DNA, DIOSynVax Ltd/ SARS-CoV-2 Pre-Clinical engineered University of and vaccine inserts Cambridge SarbecoCoronaviruses compatible with multiple delivery systems DNA DNA vaccine Ege University SARS-CoV2 Pre-Clinical DNA DNA plasmid Scancell/University SARS-CoV2 Pre-Clinical vaccine of Nottingham/ RBD&N Nottingham Trent University DNA DNA plasmid National Research SARS-CoV2 Pre-Clinical vaccine Centre, Egypt S, S1, S2, RBD&N DNA DNA with Karolinska SARS-CoV2 Pre-Clinical electroporation Institute/Cobra Biologics (OPENCORONA Project) DNA DNA with Chula Vaccine SARS-CoV2 Pre-Clinical electroporation Research Center DNA DNA Takis/Applied SARS-CoV2 Pre-Clinical DNA Sciences/Evvivax DNA Plasmid DNA, Immunomic SARS-CoV2 Pre-Clinical SARS Needle-Free Therapeutics, Delivery Inc./EpiVax, Inc./PharmaJet DNA DNA vaccine BioNet Asia SARS-CoV2 Pre-Clinical DNA msDNA Mediphage SARS-CoV2 Pre-Clinical vaccine Bioceuticals/University of Waterloo DNA DNA vaccine Entos SARS-CoV2 Pre-Clinical Pharmaceuticals DNA bacTRL-Spike Symvivo SARS-CoV2 Pre-Clinical Inactivated Inactivated + KM Biologics SARS-CoV2 Pre-Clinical JE, Zika alum Inactivated Inactivated Selcuk University SARS-CoV2 Pre-Clinical Inactivated Inactivated Erciyes SARS-CoV2 Pre- Clinical University Inactivated Inactivated National Research SARS-CoV2 Pre-Clinical whole virus Centre, Egypt Inactivated Inactivated Beijing Minhai SARS-CoV2 Pre-Clinical Biotechnology Co., Ltd. Inactivated TBD Osaka University/ SARS-CoV2 Pre-Clinical BIKEN/ NIBIOHN Inactivated Inactivated + Sinovac/Dynavax SARS-CoV2 Pre-Clinical CpG 1018 Inactivated Inactivated + Valneva/Dynavax SARS-CoV2 Pre-Clinical CpG 1018 Inactivated Inactivated Research Institute SARS-CoV2 Pre-Clinical for Biological Safety Problems, Rep of Kazakhstan Live Codon Mehmet Ali SARS-CoV2 Pre-Clinical Attenuated deoptimized Aydinlar Virus live attenuated University/ vaccines Acibadem Labmed Health Services A.S. Live Codon Codagenix/Serum SARS-CoV2 Pre-Clinical HAV, Attenuated deoptimized Institute of InfA, Virus live attenuated India ZIKV, vaccines FMD, SIV, RSV, DENV Live Codon Indian SARS-CoV2 Pre-Clinical Attenuated deoptimized Immunologicals Virus live attenuated Ltd/Griffith vaccines University Non- Sendai virus ID Pharma SARS-CoV2 Pre-Clinical Replicating Viral vector Vector Non- Adenovirus- Ankara SARS-CoV2 Pre-Clinical Replicating Viral based University Vector Non- Adeno- Massachusetts SARS-CoV2 Pre-Clinical Replicating Viral associated Eye and Vector virus vector Ear/Massachusetts (AAVCOVID) General Hospital/AveXis Non- MVA encoded GeoVax/BravoVax SARS-CoV2 Pre-Clinical LASV, Replicating Viral VLP EBOV, Vector MARV, HIV Non- Replication ReiThera/ SARS-CoV2 Pre-Clinical Replicating Viral defective LEUKOCARE/ Vector Simian Univercells Adenovirus (GRAd) encoding SARS-CoV-2S Non- MVA-S DZIF - SARS-CoV2 Pre-clinical Many replicating viral encoded German vector Center for Infection Research/IDT Biologika GmbH Non- MVA-S IDIBAPS- SARS-CoV2 Pre-clinical replicating viral Hospital vector Clinic, Spain Non- adenovirus- Altimmune SARS- CoV2 Pre-Clinical influenza Replicating Viral based Vector NasoVAX expressing SARS2-CoV spike protein Non- Adeno5-based Erciyes SARS-CoV2 Pre-Clinical Replicating Viral University Vector Non- 2nd Gen E2b- ImmunityBio, SARS-CoV2 Pre-Clinical flu, Chik, Replicating Viral Ad5 Spike, Inc. & Zika, Vector RBD, NantKwest, EBOV, Nucleocapsid Inc. LASV, Subcutaneous& HIV/SIV, Oral Cancer Non- Ad5 S Greffex SARS-CoV2 Pre-Clinical MERS Replicating Viral (GREVAX .TM. Vector platform) Non- Oral Ad5 S Stabilitech SARS-CoV2 Pre-Clinical Zika, Replicating Viral Biopharma VZV, Vector Ltd HSV-2 and Norovirus Non- adenovirus- Valo Pan-Corona Pre-Clinical Replicating Viral based + HLA- Therapeutics Vector matched Ltd peptides Non- Oral Vaccine Vaxart SARS-CoV2 Pre-Clinical InfA, Replicating Viral platform CHIKV, Vector LASV, NORV; EBOV, RVF, HBV, VEE Non- MVA Centro SARS-CoV2 Pre-Clinical Multiple Replicating Viral expressing Nacional candidates Vector structural Biotecnologia proteins (CNB-CSIC), Spain Non- Dendritic cell- University of SARS-CoV2 Pre-Clinical Replicating Viral based vaccine Manitoba Vector Non- parainfluenza University of SARS-CoV2 Pre-Clinical MERS Replicating Viral virus 5 (PIV5)- Georgia/ Vector based vaccine University expressing the of Iowa spike protein Non- Recombinant Bharat SARS-CoV2 Pre-Clinical HeV, NiV, Replicating Viral deactivated Biotech/Thomas EBOV, Vector rabies virus Jefferson LASSA, containing S1 University CCHFV, MERS Non- Influenza A National SARS-CoV2 Pre-Clinical Replicating Viral H1N1 vector Research Vector Centre, Egypt Non- Inactivated National SARS-CoV2 Pre-Clinical Replicating Viral Flu-based Center for Vector SARS-CoV2 Genetic vaccine + Engineering and Adjuvant Biotechnology (BIOTEC)/GPO, Thailand Protein Protein Subunit Research SARS-CoV2 Pre-Clinical Subunit Institute for Biological Safety Problems, Rep of Kazakhstan Protein RBD-protein Mynvax SARS-CoV2 Pre-Clinical Subunit Protein Recombinant S Izmir SARS-CoV2 Pre-Clinical Subunit protein Biomedicine and Genome Center Protein Peptide + Bogazici SARS-CoV2 Pre-Clinical Subunit novel adjuvant University Protein S subunit University of SARS-CoV2 Pre-Clinical Subunit intranasal Virginia liposomal formulation with GLA/3M052 adjs. Protein S-Protein Helix Biogen SARS-CoV2 Pre-Clinical Subunit (Subunit) + Consult, Adjuvant, Ogbomoso & E coli based Trinity Expression Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria. Protein Protein Subunit National SARS-CoV2 Pre-Clinical Subunit S, N, M&S1 Research protein Centre, Egypt Protein Protein Subunit University of SARS-CoV2 Pre-Clinical Subunit San Martin and CONICET, Argentina Protein RBD protein Chulalongkorn SARS-CoV2 Pre-Clinical Subunit fused with Fc University/GPO, of IgG + Adj. Thailand Protein Capsid-like AdaptVac SARS- CoV2 Pre-Clinical Subunit Particle (PREVENT- nCoV consortium) Protein Drosophila S2 ExpreS2ion SARS-CoV2 Pre-Clinical Subunit insect cell expression system VLPs Protein Peptide IMV Inc SARS-CoV2 Pre-Clinical Subunit antigens formulated in LNP Protein S protein WRAIR/ SARS-CoV2 Pre-Clinical Subunit USAMRIID Protein S protein + National SARS-CoV2 Pre-Clinical Influenza Subunit Adjuvant Institute of Infectious Disease, Japan/Shionogi/ UMN Pharma Protein VLP- Osaka SARS-CoV2 Pre-Clinical Subunit recombinant University/ protein + BIKEN/ Adjuvant National Institutes of Biomedical Innovation, Japan Protein microneedle Univ. of SARS-CoV2 Pre-Clinical MERS Subunit arrays S1 Pittsburgh subunit

Protein Peptide Vaxil Bio SARS-CoV2 Pre-Clinical Subunit Protein Adjuvanted Biological E SARS-CoV2 Pre-Clinical Subunit protein subunit Ltd (RBD) Protein Peptide Flow Pharma SARS-CoV2 Pre- Clinical Ebola, Subunit Inc Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine Protein S protein AJ Vaccines SARS-CoV2 Pre-Clinical Subunit Protein Ii-Key peptide Generex/EpiVax SARS-CoV2 Pre-Clinical Influenza, Subunit HIV, SARS-CoV Protein S protein EpiVax/Univ. SARS-CoV2 Pre-Clinical H7N9 Subunit of Georgia Protein Protein Subunit EpiVax SARS- CoV2 Pre-Clinical Subunit EPV-CoV-19 Protein S protein Sanofi SARS-CoV2 Pre-Clinical Influenza, Subunit (baculovirus Pasteur/GSK SARS-CoV production) Protein gp-96 Heat SARS-CoV2 Pre- Clinical NSCLC, Subunit backbone Biologics/Univ. HIV, Of Miami malaria, Zika Protein Peptide FBRI SRC SARS-CoV2 Pre-Clinical Ebola Subunit vaccine VB VECTOR, Rospotrebnadzor, Koltsovo Protein Subunit FBRI SRC SARS-CoV2 Pre-Clinical Subunit vaccine VB VECTOR, Rospotrebnadzor, Koltsovo Protein S1 or RBD Baylor SARS-CoV2 Pre-Clinical SARS Subunit protein College of Medicine Protein Subunit iBio/CC- SARS-CoV2 Pre-Clinical Subunit protein, plant Pharming produced Protein Recombinant Saint- SARS-CoV2 Pre-Clinical Subunit protein, Petersburg nanoparticles scientific (based on S- research protein and institute of other epitopes) vaccines and serums Protein COVID-19 Innovax/Xiamen SARS-CoV2 Pre-Clinical HPV Subunit XWG-03 Univ./GSK truncated S (spike) proteins Protein Adjuvanted VIDO- SARS-CoV2 Pre-Clinical Subunit microsphere InterVac, peptide University of Saskatchewan Protein Synthetic Long OncoGen SARS-CoV2 Pre-Clinical Subunit Peptide Vaccine candidate for S and M proteins Protein Oral E. coli- MIGAL SARS-CoV2 Pre-Clinical Subunit based protein Galilee expression Research system of S Institute and N proteins Protein Nanoparticle LakePharma, SARS-CoV2 Pre-Clinical Subunit vaccine Inc. Protein Plant-based Baiya SARS-CoV2 Pre-Clinical Subunit subunit Phytopharm/ (RBD-Fc + Chula Adjuvant) Vaccine Research Center Protein OMV-based Quadram SARS-CoV2 Pre-Clinical Flu A, Subunit vaccine Institute plague Biosciences Protein OMV-based BiOMViS SARS-CoV2 Pre-Clinical Subunit vaccine Srl/Univ. of Trento Protein structurally Lomonosov SARS-CoV2 Pre-Clinical rubella, subunit modified Moscow rotavirus spherical State particles of the University tobacco mosaic virus (TMV) Protein Spike-based University of SARS-CoV2 Pre-Clinical Hepatitis C Subunit Alberta Protein Recombinant AnyGo SARS-CoV2 Pre-Clinical Subunit S1-Fc fusion Technology protein Protein Recombinant Yisheng SARS-CoV2 Pre-Clinical Subunit protein Biopharma Protein Recombinant S Vabiotech SARS-CoV2 Pre-Clinical Subunit protein in IC- BEVS Protein Orally Applied SARS-CoV2 Pre-Clinical Subunit delivered, heat Biotechnology stable subunit Institute, Inc. Protein Peptides Axon SARS-CoV2 Pre-Clinical Subunit derived from Neuroscience Spike protein SE Protein Protein Subunit MOGAM SARS-CoV2 Pre-Clinical Subunit Institute for Biomedical Research, GC Pharma Protein RBD-based Neovii/Tel SARS-CoV2 Pre-Clinical Subunit Aviv University Protein Outer Intravacc/Epivax SARS-CoV2 Pre-Clinical Subunit Membrane Vesicle (OMV)- subunit Protein Outer Intravacc/Epivax SARS-CoV2 Pre-Clinical Subunit Membrane Vesicle(OMV)- peptide Protein Spike-based ImmunoPrecise/ SARS-CoV2 Pre-Clinical Subunit (epitope LiteVax screening) BV Replicating Viral YF17D Vector KU Leuven SARS-CoV2 Pre-Clinical Vector Replicating Viral Measles Vector Cadila SARS-CoV2 Pre-Clinical Vector Healthcare Limited Replicating Viral Measles Vector FBRI SRC SARS-CoV2 Pre-Clinical Vector VB VECTOR, Rospotrebnadzor, Koltsovo Replicating Viral Measles Virus DZIF - SARS-CoV2 Pre-clinical Zika, Vector (S, N targets) German H7N9, Center for CHIKV Infection Research/ CanVirex AG Replicating Viral Horsepox Tonix SARS-CoV2 Pre- Clinical Smallpox, Vector vector Pharma/Southern monkeypox expressing S Research protein Replicating Viral Live viral BiOCAD and SARS-CoV2 Pre-Clinical Influenza Vector vectored IEM vaccine based on attenuated influenza virus backbone (intranasal) Replicating Viral Recombinant FBRI SRC SARS-CoV2 Pre-Clinical Influenza Vector vaccine based VB on Influenza A VECTOR, virus, for the Rospotrebnadzor, prevention of Koltsovo COVID-19 (intranasal) Replicating Viral Attenuated Fundacao SARS-CoV2 Pre-Clinical Influenza Vector Influenza Oswaldo expressing an Cruz and antigenic Instituto portion of the Buntantan Spike protein Replicating Viral Influenza University of SARS-CoV2 Pre-Clinical Vector vector Hong Kong expressing RBD Replicating Viral Replication- IAVI/Merck SARS-CoV2 Pre-Clinical Ebola, Vector competent Marburg, VSV chimeric Lassa virus technology (VSV.DELTA.G) delivering the SARS-CoV2 Spike (S) glycoprotein. Replicating Viral VSV-S University of SARS-CoV2 Pre-Clinical HIV, Vector Western MERS Ontario Replicating Viral VSV-S Aurobindo SARS-CoV2 Pre-Clinical Vector Replicating Viral VSV vector FBRI SRC SARS-CoV2 Pre-Clinical Vector VB VECTOR, Rospotrebnadzor, Koltsovo Replicating Viral VSV-S Israel SARS-CoV2 Pre-Clinical Vector Institute for Biological Research/Weizmann Institute of Science Replicating Viral M2-deficient UW- SARS-CoV2 Pre-Clinical influenza Vector single Madison/FluGen/ replication Bharat (M2SR) Biotech influenza vector Replicating Viral Newcastle Intravacc/ SARS-CoV2 Pre- Clinical Vector disease virus Wageningen vector (NDV- Bioveterinary SARSCoV- Research/ 2/Spike) Utrecht Univ. Replicating Viral Avian The SARS-CoV2 Pre-Clinical Vector paramyxovirus Lancaster vector University, (APMV) UK RNA Self- Gennova SARS-CoV2 Pre-Clinical amplifying RNA RNA mRNA Selcuk SARS-CoV2 Pre-Clinical University RNA LNP-mRNA Translate SARS- CoV2 Pre-Clinical Bio/Sanofi Pasteur RNA LNP-mRNA CanSino SARS-CoV2 Pre-Clinical Biologics/Precision NanoSystems RNA LNP- Fudan SARS-CoV2 Pre-Clinical encapsulated University/ mRNA Shanghai cocktail JiaoTong encoding VLP University/ RNACure Biopharma RNA LNP- Fudan SARS-CoV2 Pre-Clinical encapsulated University/ mRNA Shanghai encoding RBD JiaoTong University/ RNACure Biopharma RNA Replicating Centro SARS-CoV2 Pre-Clinical Defective Nacional SARS-CoV-2 Biotecnologia derived RNAs (CNB-CSIC), Spain RNA LNP- University of SARS- CoV2 Pre-Clinical MERS encapsulated Tokyo/Daiichi- mRNA Sankyo RNA Liposome- BIOCAD SARS-CoV2 Pre-Clinical encapsulated mRNA RNA Several mRNA RNAimmune, Inc. SARS-CoV2 Pre-Clinical candidates RNA mRNA FBRI SRC SARS-CoV2 Pre-Clinical VB

VECTOR, Rospotrebnadzor, Koltsovo RNA mRNA China SARS-CoV2 Pre-Clinical CDC/Tongji University/Stermina RNA LNP-mRNA Chula SARS-CoV2 Pre-Clinical Vaccine Research Center/University of Pennsylvania RNA mRNA in an eTheRNA SARS-CoV2 Pre-Clinical intranasal delivery system RNA mRNA Greenlight SARS-CoV2 Pre-Clinical Biosciences RNA mRNA IDIBAPS- SARS-CoV2 Pre-Clinical Hospital Clinic, Spain VLP VLP Bezmialem SARS-CoV2 Pre-Clinical Vakif University VLP VLP Middle East SARS-CoV2 Pre-Clinical Technical University VLP Enveloped VBI SARS-CoV-2, Pre-Clinical CMV, Virus-Like Vaccines Inc. SARS-CoV, & GBM, Zika Particle MERS-CoV (eVLP) VLP S protein IrsiCaixa SARS-CoV2 Pre-Clinical integrated in AIDS HIV VLPs Research/IRTA- CReSA/Barcelona Supercomputing Centre/Grifols VLP VLP + Mahidol SARS-CoV2 Pre-Clinical Adjuvant University/The Government Pharmaceutical Organization (GPO)/Siriraj Hospital VLP Virus-like Navarrabiomed, SARS-CoV2 Pre-Clinical particles, Oncoimmunology lentivirus and group baculovirus vehicles VLP Virus-like Saiba GmbH SARS-CoV2 Pre- Clinical particle, based on RBD displayed on virus-like particles VLP ADDomerTM Imophoron SARS-CoV2 Pre-Clinical multiepitope Ltd and display Bristol University's Max Planck Centre VLP Unknown Doherty SARS-CoV2 Pre-Clinical Institute VLP VLP OSIVAX SARS-CoV1 Pre-Clinical SARS-CoV2 VLP eVLP ARTES SARS-CoV2 Pre-Clinical malaria Biotechnology VLP VLPs Univ. of Sao SARS-CoV2 Pre-Clinical peptides/whole Paulo virus

For those that prefer visuals:

---

Got that? Here’s more from the patent:

---

Any combination of one or more computer readable medium(s) may be utilized for some embodiments of the invention. The computer readable medium may be a computer readable signal medium or a computer readable storage medium. A computer readable storage medium may be, for example, but not limited to, an electronic, magnetic, optical, electromagnetic, infrared, or semiconductor system, apparatus, or device, or any suitable combination of the foregoing. More specific examples (a non-exhaustive list) of the computer readable storage medium would include the following: an electrical connection having one or more wires, a portable computer diskette, a hard disk, a random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or Flash memory), an optical fiber, a portable compact disc read-only memory (CD-ROM), an optical storage device, a magnetic storage device, or any suitable combination of the foregoing. In the context of this document, a computer readable storage medium may be any tangible medium that can contain, or store a program for use by or in connection with an instruction execution system, apparatus, or device.

A computer readable signal medium may include a propagated data signal with computer readable program code embodied therein, for example, in baseband or as part of a carrier wave. Such a propagated signal may take any of a variety of forms, including, but not limited to, electro-magnetic, optical, or any suitable combination thereof. A computer readable signal medium may be any computer readable medium that is not a computer readable storage medium and that can communicate, propagate, or transport a program for use by or in connection with an instruction execution system, apparatus, or device.

In some embodiments, actual measured geolocation data of each individual is monitored to assess their potential to meet other people. In some embodiments, people which show high number movements during the day in areas where other people are located will receive a high score. In some embodiments, actual geolocation data of each individual is monitored using one or more of:

1. Electronic devices, for example the location provided by the GPS of their own cellphones;

2. Using face recognition technology based on one or more of: a) video surveillance data received from available sources, for example street cameras, ATM's, private surveillance cameras in stores, buildings and houses, etc.; b) social media.

3. Digital activity, for example credit card usage, IP address used while using a computer or an electronic device, antennas that receive data while performing a phone call. Optionally or additionally, such actual geolocation data is used instead of or in addition to actually identifying contact between people.
Historical Medical Data of the Individual

In some embodiments, historical medical data of each individual is assessed to provide a score. For example, as mentioned above, individuals with chronic coughing will receive a high score since they have potentially a higher chance to transmit the infectious disease/virus/pathogen. In some embodiments, individuals having a background condition that enhances the chances of transmitting the disease will receive a high score.

---

^→ Pause. This description is disconcerting for a variety of reasons. This will be an endless post if I address all of them. So I am going to focus on a few things that stuck out to me. I don’t have the expertise to assess any of it with any modicum of authority, but sometimes I think that’s helpful. Sometimes completely naïve inquiry can be illuminating. I don’t know wtf most of this stuff is…I’m just asking innocent questions that I find relevant. Hopefully I’m completely wrong. But for now, let’s entertain a few conspiracy theories. As usual, I am NOT saying this is what’s going down. I’m just observing that the opportunity is there.

→ So let’s review…Rosalind is making data human - with their biobank tracking, visual analysis, interpretation, and cloud-based data sharing of genomic datasets produced with Next Generation Sequencing (NGS), NanoString instruments, and other multi-omic methods. There’s a patent that lists a lot of “devices” and “mediums” and “vaccines” that sure would integrate well into the Rosalind description. Moving on….

NanoString Instruments sound fun. Who makes those?

Let’s look at this one:

→ I wonder what they’re interested in. Oh, here it is:

Malvern Panalytical

NanoSight NTA

The technique uses low sample volumes with little sample preparation which, along with minimal instrument consumables, reduces running costs on a day to day basis.  The technique is also non-destructive and the sample can be recovered if required.

NanoSight NTA systems support work within ISO19430: 2016 Particle Tracking Analysis (PTA) Method and ASTM E2834-12 (2012) Standard Guide for Measurement of Particle Size Distribution of Nanomaterials in Suspension by Nanoparticle Tracking Analysis (NTA).

Applications include:

• Exosomes, microvesicles and extracellular vesicles characterization.

• Viral vaccine research and development.

• Development of drug delivery systems.

• Protein aggregation studies.

• Nanotoxicology.

---

→ Ok, so ROSALIND Research provides visual analysis, interpretation, and cloud-based data sharing of genomic datasets produced with Next Generation Sequencing (NGS), NanoString instruments, and other multi-omic methods. Instruments like this NS300 by Malvern Panalytical.

The NS300 allows rapid analysis of the size distribution and concentration of all types of nanoparticles from 0.01 - 1 µm* in diameter, depending on the instrument configuration and sample type.

There are a wide variety of applications in which the measurement of particle / nanoparticle concentration  is critically important, including:

• Biopharmaceutical (including vaccine) development, manufacture and quality assurance, in which the titer of virus is related to the viral dosage and resultant performance of the vaccine.

• Protein aggregation studies, including accelerated stress testing and stability studies.

• Differentiation and concentration measurement of sub-visible protein aggregates and silicone oil droplets in pre-filled syringe aggregation studies.

• Drug delivery in which the biological response to the drug may be influenced by the concentration and particle size of the delivery vector.

• Exosomes and microvesicle research in which the concentration of specific exosomes and microvesicles may be indicative of the onset of disease and therefore is of interest in the area of disease diagnostics.  

• Nanoparticle toxicology in which the concentration of particles within a biological or ecological environment may influence the biological response to the nanoparticles from a toxicity perspective.

• Regulatory requirements as a result of the EU definition of a nanomaterial in which number based distributions determine whether a material is classed as a nanomaterial or not.

---

So I’m trying not to let my conspiracy tendencies get the best of me. Surely there wouldn’t be some traceable, trackable, nano-thing in an injectable product (that most of the world just took) that would fit into the description of that concerning patent. Right?

They can’t inject something like that.

Right?

---

The first transformable nano-scale electronic devices are finally here

Making the most of these slippery interfaces, they developed electronic devices made of single-atom-thick sheets of a substance called graphene attached to gold wires that can be transformed into a variety of different configurations easily.

One area where it is certain to have an impact is quantum science research.

“It could fundamentally change how people do research in this field,” Sanchez-Yamagishi said.

“Researchers dream of having flexibility and control in their experiments, but there are a lot of restrictions when dealing with nanoscale materials,” he added in the press statement. “Our results show that what was once thought to be fixed and static can be made flexible and dynamic.”

---

Only conspiracy theorists talk about graphene. So we KNOW they aren’t using that in anything injectable. Because they said they aren’t. And they ALWAYS tell us the truth. Remember when they told us all that truth about the vaccines, starting with calling them vaccines instead of countermeasures? Clinical trials. 100% effective. Stops transmission. Stays in deltoid. Prevents hospitalization. Prevents death. Doesn’t alter DNA.

I just want to be crystal clear. There is DEFINITELY nothing other than what they, the historical truth tellers, tell us is in these shots. Cool.

---

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

Abstract

The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this “virus” nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using engineered nanocarriers, blocking the initial interactions of viral spike glycoprotein with host cell surface receptors, and disruption of virion construction. Controlling and eliminating the spread and reoccurrence of this pandemic demands a safe and effective vaccine strategy. Nanocarriers have potential to design risk-free and effective immunization strategies for severe acute respiratory syndrome coronavirus 2 vaccine candidates such as protein constructs and nucleic acids. We discuss recent as well as ongoing nanotechnology-based therapeutic and prophylactic strategies to fight against this pandemic, outlining the key areas for nanoscientists to step in.

Graphene oxide (GO) has been extensively used as a nanocarrier for biochemical molecules due to its high specific surface area, mechanical properties, and high aspect ratio.¹

Injecting biomedical electronics for monitoring and therapy of body organs

To overcome these problems, one of the device classes that researchers have fabricated are relatively novel, miniaturized needle-like carriers in high aspect ratio structures. They are used to deliver tiny sensors and stimulation tools inside the body via minimally invasive injection or insertion into a specific area of an organ.

Device Can Read Emotions by Bouncing Wireless Signals off Your Body

Using a device smaller than a Wi-Fi router, researchers at MIT were able to monitor a person's breathing and heartbeat wirelessly. These measurements were then fed into a machine-learning algorithm that classified the subject’s emotion as excited, happy, angry or sad. The accuracy was similar to state-of-the-art wired approaches, the scientists said. [5 Ways Your Emotions Influence Your World (and Vice Versa)]

The inventors say potential applications include health care systems that detect if you're getting depressed before you do, "smart" homes that can tune lighting and music to your mood or tools that allow filmmakers to get real-time feedback on their audience's reaction.

---

→ Or applications could include tracking, tracing, and controlling useless eaters humans through an injectable, potentially programmable….nah, that’s crazy. How could they do that???

---

Metal organic frameworks (MOFs)

MOF characterization solutions to help you build robust structures

Metal organic frameworks (MOFs) are hybrid crystal covalent structures created by reacting organic molecules with metal ions. Not only are they more durable than organic crystals, but because of their nano-scale interconnected voids, they have unrivaled potential for trapping, storing, and catalyzing ions and molecules.

Thanks to these abilities, MOFs can add significant value in several applications, including gas storage and separation, liquid separation and purification, electrochemical energy storage, catalysis, or drug delivery. They can also be used in gas sensor devices that measure and respond to this capture process.

Spanish study finds Pfizer vaccine contains high levels of TOXIC graphene oxide

Chinese Patent CN112220919A CV Vaxx contains graphene oxide 

A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity

Here, we propose an ultrafast, low-temperature, universal self-assembly route to integrate a cancer antigen and an immunopotentiator into each nanoparticle consisting of MS as a core container and MOF as a gatekeeper for fabricating MS@MOF cancer vaccines as the magic bullet for combination cancer immunotherapy.

‘Metal-Organic Frameworks’ a Solution to Non-Refrigerated Vaccines: CSIRO

CSIRO researchers have found a possible solution to the problem by encapsulating live virus vaccines with a dissolvable crystalline material called MOFs, which acts as a scaffold, protecting vaccine molecules from heat stress and eliminating the necessity for refrigeration.

Prior to administration, a solution will then be added to dissolve the MOF, exposing the vaccine particles.

There are currently two approaches to address temperature stress for non-refrigerated vaccines; either engineer the vaccine to increase its stability or add stabilising agents to the solution.

Whilst engineering vaccines is difficult and complex, there have been several studies exploring the potential of stabilising agents. A Canadian study in 2019 has shown that dried herpes and Influenza A virus vaccines have been successfully stored at 40 degrees for up to two and three months respectively in low-cost sugar films. Additionally, a 2016 study from the UK showed that adenoviral vaccines can be stable for up to 10 days at 37 degrees by adding polyethylene glycol, nanoparticle gold, and table sugar to the solution.

The CSIRO study conducted found MOFs protected the integrity of live viral vaccines for up to 12 weeks with decreasing effectiveness as time increases at an overall temperature of 37 degrees Celsius. Without refrigeration, the vaccine would normally last only a few days.

The research focused on two different types of live viruses; a Newcastle Disease vaccine designed to protect poultry and a strain of the Influenza A vaccine.

The CSIRO advertises itself as having the world’s “first technology to manufacture industrial scale quantities” of MOFs as a commercial outlet for the organisation on its website.

The graphene made by the CSIRO is composed of soybean and waste oils, which is cheaper to make than traditional graphene. Soybean oil, with heat, breaks down into a range of carbon building units that are essential for the synthesis of graphene. The team also transformed other types of renewable and even waste oil groups, such as those leftover from barbecues or cooking, into low-cost graphene films.

Graphical Abstract

Plasmas, the 4^th state of matter, uniformly transform natural precursors with different chemical composition in solid, liquid, and gas states into the same functional vertical graphenes in a single-step process within a few minutes. Functional vertical graphenes show reliable biosensing properties, strong binding with proteins, and improved adhesion to substrates.

MOF-Jet: Novel powdered vaccine can be puffed through your skin

Introducing MOF-Jet, a powdered vaccine that can be puffed through your skin, borne out of pandemic-induced boredom.

Scientists at The University of Texas, Dallas, have developed a vaccine that does not require refrigeration and a system driven by compressed gas - it could 'easily deliver therapeutics against cancer and other diseases in a relatively painless way', a press release states.

The Growth of Metal–Organic Frameworks in the Presence of Graphene Oxide: A Mini Review

Ascribed to the distinctive structural and functional properties of GO, the nucleation and crystallization process of MOFs could be altered/promoted, forming MOF/GO composite materials with different nanostructures.

Graphene quantum dot based materials for sensing, bio-imaging and energy storage applications: a review

2.1.1 Liquid exfoliation

Liquid exfoliation (LE) of the 2D materials has drawn huge interest due to the scalability. LE through ultrasonication is the most capable behaviours to yield nanosheets with numerous benefits like low-cost fabrication, ease in operation and minimize environmental impact. During this process, if the graphite as a precursor is exfoliated to graphene layers then GQDs with good crystallinity can be prepared by the LE method.

2.2.1 Microwave-assisted hydrothermal method

The hydrothermal method usually consumes a long time to produce GQDs. Therefore, currently a fast method was oppressed by assisting with microwave i.e., microwave-assisted hydrothermal (MAH) method.⁶⁵ By assisting with a microwave, so called MAH is utilized to synthesize the GQDs that share both the benefits of microwave and hydrothermal techniques.⁶⁶ It was developed by Lau's group to prepare water-soluble GQDs using glucose as a precursor. The heating of microwave that provides simultaneous, homogeneous, and fast heating leads to the formation of the uniform size distribution of quantum dots

5.2 Biomedical application

5.2.1 Bio-imaging

Bio-imaging has an important role in both research and clinical application and permits observation and learning of biological processes from subcellular to the small animal level. Investigators were able to find out the initial stage of ailment and to screen the behaviour response with the suitable bioimaging probes.¹⁵¹ Recently, GQDs were labelled as a class of fluorescent nanomaterial having unique optical properties that can lead to excellent results based on bioimaging for the diagnosis and treatment of diseases in biological systems (Table 4) owing to their 0D structure, low toxicity, high solubility, biocompatibility and chemical inertia. In the physiological circumstance, GQDs are the most sought after materials these days. For example, Zhu et al.²¹ performed experiments by adding up to 400 micrograms along with 150 mL of culture medium (10⁴ cells) which could not weaken the cell activity as suggested by the MTT assay as shown in Fig. 16a. GQDs through the cell's membrane (excitation at 405 nm) were observed using a confocal fluorescence microscope by surveillance of the bright green area inside the cells as shown in Fig. 16b and c. Thus, the bioimaging is dependent upon the excitation behaviour of the GQDs which leads to several visible results dependent on PL. The resultant report was consist of excitation changes in the range of light from green to yellow colour at 488 nm as shown in Fig. 16d.

Fig. 16 Microscopic analysis for imaging and cellular toxicity of GQDs. (a) Cells viability of MG-63 cell with corresponding amount of GQDs. (b–d) are the images of washed cells under bright field, 405 nm, 488 nm excitations, respectively. Reproduced with permission fromref. 21, copyright 2011, The Royal Society of Chemistry.

5.2.2 Biosensing

The optical properties of the GQDs can be utilized for biosensing. In addition to bioimaging, biosensing is also based on the detection of an emitted photon through PL of GQDs. The GQDs assisted biosensor exploits the affinity between analyte biomolecule and GQDs functional group to detect the presence of biomolecule. The ions essential for biological processes or responsible for acute toxicity have to be efficiently transported and regulated at the cellular level.

5.2.3 Drug delivery systems

The outstanding chemical and tunable physical properties, along with ease in distinct surface functionalization make GQDs promising material for drug delivery systems.¹⁶⁶ The graphene nanosheets size-dependent coupling with DNA molecules was investigated by Zhou et al.¹⁶⁷ The study revealed that the DNA molecule intercalating ability is more visible for small lateral size GQDs.¹⁶⁷

---

Let’s round this out with another trip to the FedRAMP Marketplace.

I can’t help myself. The shopping is simply to die for.

Armis, FedRAMP Edition (AFE) is an agentless, enterprise-class security platform purpose-built to help organizations discover and secure managed, unmanaged, and IoT devices, including medical devices and industrial control systems (ICS).. Armis discovers every managed, unmanaged, and IoT device in any environment, analyzes device behavior to identify risks, vulnerabilities or attacks, and protects critical business information and systems. Armis easily integrates with existing security products. AFE passively monitors wired and wireless traffic in the environment to identify every device and to understand its behavior without disruption. AFE analyzes this data in the AFE Risk Engine which uses device profiles and characteristics from the AFE Device Knowledgebase to identify each device, assess its risks & vulnerabilities, detect threats, and recommend remediation actions. Visibility AFE closes the Continuous Diagnostic and Mitigation Dashboard visibility gap with unmanaged and IoT devices. AFE discovers and classifies every managed, unmanaged, and IoT device in the environment including servers, laptops, smartphones, VoIP phones, smart TVs, IP cameras, printers, 5G, HVAC controls, medical devices, industrial controls, and more. AFE can even identify off-network devices using Wi-Fi, Bluetooth, and other protocols in any environment. The comprehensive device inventory that AFE generates includes critical information such as device manufacturer, model, serial number, location, username, operating system, installed applications, and connections made over time. In addition to discovering and classifying a device, AFE calculates its risk score based on factors such as vulnerabilities, known attack patterns, as well as the behaviors observed of each device in the environment. This risk score helps security teams understand their attack surface and meet compliance with regulatory frameworks that require identification and prioritization of vulnerabilities. Insights The AFE Risk Engine continuously monitors the behavior of every device in the environment for behavioral anomalies. Working with the AFE Device Knowledgebase, AFE compares the real-time behavior of each device with:

• Historical device behavior

• Behavior of similar devices in the Customer's environment

• Behavior of similar devices in other environments

Agencies using this service

• Defense Information Systems Agency

• Department of Defense

• Department of Health and Human Services

• Office of the National Coordinator for HealthIT

---

I’m just going to leave you with one more look at that patent. I’m sure all of these things are completely unrelated.

---

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

In some embodiments of the invention, private information about a person's activity and/or persons they came in contact with and/or geolocations are maintained on that person's mobile device and used to determine a priority for that person (e.g., by assessing the number of contacts and overall risk of spreading disease due to typical behavior of that person). Optionally, the mobile device is used to broadcast, optionally in an anonymous manner, the score, so that, it may be determined, for example, by a central computer, the distribution of scores across the population.

In some embodiments of the invention, a process of using the method includes:

(a) Learning the behavior of individuals. This may be done, for example, using existing contact tracking methods and/or using methods as discussed herein. Optionally, such learned behavior is maintained in privacy and/or collected in an anonymous manner or processed as it is collected, to preserve anonymity.

(b) Scoring, which can be based, for example, on number, variety and/or quality of contacts, degree of bridging between subpopulations, risk to individual, risk to others the individual is in contact with, other facts that affect spreading (e.g., chronic cough) and/or existing immunity.

In some embodiments, actual geolocation data of each individual is monitored using one or more of:

1. Electronic devices, for example the location provided by the GPS of their own cellphones;

2. Using face recognition technology based on one or more of: a) video surveillance data received from available sources, for example street cameras, ATM's, private surveillance cameras in stores, buildings and houses, etc.; b) social media.

3. Digital activity, for example credit card usage, IP address used while using a computer or an electronic device, antennas that receive data while performing a phone call. Optionally or additionally, such actual geolocation data is used instead of or in addition to actually identifying contact between people.
Historical Medical Data of the Individual

In some embodiments, historical medical data of each individual is assessed to provide a score.

Actual Medical Data of the Individual

In some embodiments, during the pandemic, every new medical data concerning each individual is monitored to assess if the new data indicates a change in the medical status of the individual regarding their potential to infect others. Using the example above, if a person is diagnosed with chronic coughing it will increase their score (e.g., in general and/or per contact).

Third Party Information Regarding the Individual

In some embodiments, third party information from individuals informing on others will be assessed to decide if the information needs to affect the score.

---

So that’s it, friends.

Shitfuckery abounds.

Stay on your toes.